BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, Rujirojindakul P, Kanjana S, Theamboonlers A, Tangkijvanich P. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One. 2015;10:e0126764. [PMID: 25962112 DOI: 10.1371/journal.pone.0126764] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Hongjaisee S, Doungjinda N, Khamduang W, Carraway TS, Wipasa J, Debes JD, Supparatpinyo K. Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. Int J Infect Dis 2021;102:440-5. [PMID: 33130211 DOI: 10.1016/j.ijid.2020.10.082] [Reference Citation Analysis]
2 Li XM, Qiu RX, Song CH, Huang QH, Wang XD, Hu ZT, He XZ, Ye XY, Huang XG, Zheng FF, Lin GX. Genotype and genetic variation of HCV infections with low-risk factors in Putian coastal regions, China. Epidemiol Infect 2017;145:3385-97. [PMID: 29081304 DOI: 10.1017/S0950268817002357] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Reference Citation Analysis]
4 Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VW, Wong GL, Nguyen MH. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol. 2017;112:1111-1119. [PMID: 28440303 DOI: 10.1038/ajg.2017.123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
5 Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-sobol H, Mo H, Brainard DM, Yang Y, Dao L, Wang G, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology 2019;4:127-34. [DOI: 10.1016/s2468-1253(18)30343-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 16.3] [Reference Citation Analysis]
6 Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Reference Citation Analysis]
8 Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, Shah S, Mamun-al-mahtab, Abbas Z, Johnston J, Tanwandee T, Wallace J. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. The Lancet Gastroenterology & Hepatology 2016;1:248-55. [DOI: 10.1016/s2468-1253(16)30031-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
9 Solomon SS, Boon D, Saravanan S, Srikrishnan AK, Vasudevan CK, Balakrishnan P, Persaud D, Ray SC, Mehta S, Mehta SH. Diversity of hepatitis C virus infection among HIV-infected people who inject drugs in India. Virusdisease 2019;30:490-7. [PMID: 31897414 DOI: 10.1007/s13337-019-00553-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Sukthong P, Poovorawan K, Tangkijvanich P, Poovorawan Y. Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy. PLoS One 2018;13:e0202991. [PMID: 30138441 DOI: 10.1371/journal.pone.0202991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Nouhin J, Bollore K, Castera-Guy J, Prak S, Heng S, Kerleguer A, Rubbo PA, Rouet F, Tuaillon E. Analytical and field evaluation of the Biocentric Generic HCV assay on open polyvalent PCR platforms in France and Cambodia. J Clin Virol 2018;108:53-8. [PMID: 30245364 DOI: 10.1016/j.jcv.2018.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wasitthankasem R, Vichaiwattana P, Auphimai C, Siripon N, Klinfueng S, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ 2017;5:e4008. [PMID: 29134150 DOI: 10.7717/peerj.4008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
14 Berto A, Day J, Van Vinh Chau N, Thwaites GE, My NN, Baker S, Darton TC. Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. BMC Infect Dis 2017;17:260. [PMID: 28399806 DOI: 10.1186/s12879-017-2360-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
15 Han WM, Colby DJ, Khlaiphuengsin A, Apornpong T, Kerr SJ, Ubolyam S, Kroon E, Phanuphak N, Vasan S, Matthews GV, Avihingsanon A, Ruxrungtham K, Phanuphak P, Tangkijvanich P. Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand. Liver Int 2020;40:2104-9. [PMID: 32574394 DOI: 10.1111/liv.14578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Biswas A, Gupta D, Saha K, Sarkar K, Firdaus R, Sadhukhan PC. Emerging new HCV strains among intravenous drug users and their route of transmission in the north eastern state of Mizoram, India. Mol Phylogenet Evol 2017;116:239-47. [PMID: 28916154 DOI: 10.1016/j.ympev.2017.09.006] [Reference Citation Analysis]
17 Durier N, Yunihastuti E, Ruxrungtham K, Kinh NV, Kamarulzaman A, Boettiger D, Widhani A, Avihingsanon A, Huy BV, Syed Omar SF, Sanityoso A, Chittmittrapap S, Dung NT, Pillai V, Suwan-Ampai T, Law M, Sohn AH, Matthews G. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. J Viral Hepat 2017;24:187-96. [PMID: 27917597 DOI: 10.1111/jvh.12630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Hudu SA, Niazlin MT, Nordin SA, Tan SS, Omar H, Shahar H, Mutalib NA, Sekawi Z. Genetic diversity of hepatitis B co-infection with hepatitis C, D and E viruses among Malaysian chronic hepatitis B patients. Afr Health Sci 2018;18:1117-33. [PMID: 30766578 DOI: 10.4314/ahs.v18i4.33] [Reference Citation Analysis]
19 Manomaivat T, Pongsiriwet S, Kuansuwan C, Thosaporn W, Tachasuttirut K, Iamaroon A. Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study. J Investig Clin Dent 2018;9:e12316. [PMID: 29345111 DOI: 10.1111/jicd.12316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Hepatobiliary Pancreat Dis Int 2019;18:143-8. [PMID: 30558838 DOI: 10.1016/j.hbpd.2018.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Chantratita W, Song KS, Nimse SB, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Sonawane MD, Warkad SD, Kim T. 6 HCV Genotyping 9G test for HCV 1a, 1b, 2, 3, 4 and 6 (6a, 6f, 6i and 6n) with high accuracy. J Virol Methods 2017;246:95-9. [PMID: 28456667 DOI: 10.1016/j.jviromet.2017.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
23 Smith D, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2019;69:1861-72. [PMID: 29425396 DOI: 10.1002/hep.29837] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
24 Huang K, Chen J, Xu R, Jiang X, Ma X, Jia M, Wang M, Huang J, Liao Q, Shan Z, Dailey C, Song X, Lu L, Li C, Rong X, Zhang M, Fu Y. Molecular evolution of hepatitis C virus in China: A nationwide study. Virology 2018;516:210-8. [PMID: 29407379 DOI: 10.1016/j.virol.2018.01.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Yong KSM, Her Z, Chen Q. Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells 2019;8:E604. [PMID: 31213010 DOI: 10.3390/cells8060604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
26 Naing C, Sitt T, Aung AT, Aung K. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore). 2015;94:e1234. [PMID: 26222859 DOI: 10.1097/md.0000000000001234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis 2016;16:163. [PMID: 27090517 DOI: 10.1186/s12879-016-1488-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
30 Thedja MD, Wibowo DP, El-Khobar KE, Ie SI, Setiawan L, Murti IS, Muljono DH; Turyadi. Improving Linkage to Care of Hepatitis C: Clinical Validation of GeneXpert® HCV Viral Load Point-of-Care Assay in Indonesia. Am J Trop Med Hyg 2021:tpmd201588. [PMID: 33999849 DOI: 10.4269/ajtmh.20-1588] [Reference Citation Analysis]
31 Younossi ZM, Stepanova M, Chan HLY, Lee MH, Yu ML, Dan YY, Choi MS, Henry L. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Medicine (Baltimore) 2016;95:e2702. [PMID: 26945356 DOI: 10.1097/MD.0000000000002702] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 5.2] [Reference Citation Analysis]
32 Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Mumtaz S, Ahmed J, Gul A, Tariq SA, Siraj S, Sarwar T. Genetic Diversity of Hepatitis C Virus Genotype 3a Based on Complete Core Protein in Peshawar, Pakistan. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.98942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
35 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Pawlotsky J. DAA failures in African patients with “unusual” HCV subtypes: Hey! Didn’t you know there was another world? Journal of Hepatology 2019;71:1070-2. [DOI: 10.1016/j.jhep.2019.09.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
38 Tung HD, Lee PL, Chen JJ, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Wu YH, Pang MG, Lin CH, Hou CY, Tsai HH, Wu LC, Lee C. Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution. Viruses 2021;13:1316. [PMID: 34372521 DOI: 10.3390/v13071316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chantratita W, Song KS, GunHo C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD, Kim T. 6 HCV genotyping 9G test and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus genotyping. J Virol Methods 2017;239:1-8. [PMID: 27793646 DOI: 10.1016/j.jviromet.2016.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
40 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thaneskongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Suwanpatoomlerd S, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence. PLoS One 2017;12:e0177022. [PMID: 28475637 DOI: 10.1371/journal.pone.0177022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
42 Poovorawan K, Pan-Ngum W, White LJ, Soonthornworasiri N, Wilairatana P, Wasitthankasem R, Tangkijvanich P, Poovorawan Y. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. PLoS One 2016;11:e0163095. [PMID: 27631382 DOI: 10.1371/journal.pone.0163095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
43 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
44 Ciccozzi M, Lai A, Zehender G, Borsetti A, Cella E, Ciotti M, Sagnelli E, Sagnelli C, Angeletti S. The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. J Med Virol 2019;91:1707-24. [PMID: 31243773 DOI: 10.1002/jmv.25526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Yusrina F, Chua CW, Lee CK, Chiu L, Png TS, Khoo MJ, Yan G, Lee GH, Yan B, Lee HK. Comparison of cobas HCV GT against Versant HCV Genotype 2.0 (LiPA) with confirmation by Sanger sequencing. J Virol Methods 2018;255:8-13. [PMID: 29428399 DOI: 10.1016/j.jviromet.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Nouhin J, Iwamoto M, Prak S, Dousset JP, Phon K, Heng S, Kerleguer A, Le Paih M, Dussart P, Maman D, Rouet F. Molecular epidemiology of hepatitis C virus in Cambodia during 2016-2017. Sci Rep 2019;9:7314. [PMID: 31086236 DOI: 10.1038/s41598-019-43785-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
47 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
48 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
49 Warkad SD, Nimse SB, Song KS, Kim T. HCV Detection, Discrimination, and Genotyping Technologies. Sensors (Basel) 2018;18:E3423. [PMID: 30322029 DOI: 10.3390/s18103423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
50 Chaiwong S, Sistayanarain A. Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors. J Med Virol 2016;88:1785-90. [PMID: 27018495 DOI: 10.1002/jmv.24536] [Reference Citation Analysis]
51 Win NN, Kanda T, Nakamoto S, Yokosuka O, Shirasawa H. Hepatitis C virus genotypes in Myanmar. World J Gastroenterol 2016; 22(27): 6095-6099 [PMID: 27468202 DOI: 10.3748/wjg.v22.i27.6095] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]